<!DOCTYPE html>
<!-- saved from url=(0083)https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm -->
<html class="" data-reactroot=""><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><script src="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/analytics.js.download" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app220.us.archive.org';v.server_ms=248;archive_analytics.send_pageview({});});</script>
<script type="text/javascript" src="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/bundle-playback.js.download" charset="utf-8"></script>
<script type="text/javascript" src="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/wombat.js.download" charset="utf-8"></script>
<script type="text/javascript">
  __wm.init("https://web.archive.org/web");
  __wm.wombat("https://baike.sogou.com/kexue/d11080.htm","20221025090628","https://web.archive.org/","web","/_static/",
	      "1666688788");
</script>
<link rel="stylesheet" type="text/css" href="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/banner-styles.css">
<link rel="stylesheet" type="text/css" href="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/iconochive.css">
<!-- End Wayback Rewrite JS Include -->
<meta name="save" content="history"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="baidu-site-verification" content="VWGb6TyYx8"><meta content="选择性COX2抑制剂 - 搜狗科学百科" name="keywords"><meta content="搜狗科学百科是一部有着平等、协作、分享、自由理念的网络科学全书，为每一个互联网用户创造一个涵盖所有领域知识、服务的中文知识性平台。" name="description"><meta http-equiv="x-dns-prefetch-control" content="on"><meta name="server" baike="235" ip="210" env="online"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025090628/https://cache.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025090628/https://hhy.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025090628/https://pic.baike.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025090628/https://ugc.qpic.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025090628/https://xui.ptlogin2.qq.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025090628/https://q1.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025090628/https://q2.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025090628/https://q3.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025090628/https://q4.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025090628/https://q.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025090628/https://img01.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025090628/https://img02.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025090628/https://img03.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221025090628/https://img04.sogoucdn.com/"><link rel="Shortcut Icon" href="https://web.archive.org/web/20221025090628im_/https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link rel="Bookmark" href="https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link href="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/base_b849887.css" rel="stylesheet"><link href="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/detail_378aed5.css" rel="stylesheet"><link href="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/inviteAudit_7894507.css" rel="stylesheet"><link rel="stylesheet" href="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/highlight.min.css"><title>选择性COX2抑制剂 - 搜狗科学百科</title><style>.onekey-close {
	position: absolute;
	top: 16px;
	right: 16px;
	width: 24px;
	height: 24px;
	background: url(//web.archive.org/web/20221025113757/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	text-indent: -999em;
	background-size: 84px;
	background-position: -63px 0;
}

.onekey-login {
	position: absolute;
	top: 16.4%;
	left: 0;
	right: 0;
	width: 100%;
}

/* .onekey-login-img {
    width: 75px;
    height: 75px;
    background: url("https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/images/sprite_wap_baike.png") no-repeat;
    background-size: 100px 91px;
    background-position: 0 0;
    background-repeat: no-repeat;
    margin: 0 auto;
} */

.onekey-login-title {
	text-align: center;
	padding-bottom: 3px;
	font-size: 21px;
	font-weight: bold;
	line-height: 30px;
	color: #000;
}

.onekey-login-txt {
	text-align: center;
	font-family: PingFangSC;
	font-size: 14px;
	line-height: 20px;
	color: #8f8f8f;
}

.onekey-login-qq,
.onekey-login-wx,
.onekey-login-phone {
	display: block;
	width: 245px;
	height: 54px;
	border-radius: 45px;
	text-align: center;

	margin: 0 auto;
	font-size: 17px;
	line-height: 24px;
	color: #000;
	/* padding: 16px 77px; */
	border-radius: 12px;
	border: solid 1px #e0e0e0;
}
.onekey-qq-content,
.onekey-vx-content,
.onekey-phone-content {
	display: inline-block;
	margin-top: 16px;
}
.onekey-qq-content {
	padding: 0 5px;
}

.onekey-login-qq {
	margin-top: 48px;
	margin-bottom: 24px;
}

.onekey-login-qq:before {
	display: inline-block;
	content: "";
	width: 20px;
	height: 20px;
	background: url(//web.archive.org/web/20221025113757/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 80px;
	background-position: -20px 0;
	vertical-align: top;
	margin: 17px 8px 0 0;
}

.onekey-login-wx {
	margin-bottom: 24px;
}

.onekey-login-wx:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221025113757/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: 0 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-login-phone {
}

.onekey-login-phone:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221025113757/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: -42px 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-fixed {
	z-index: 100;
	position: fixed;
	top: 0;
	bottom: 0;
	left: 0;
	right: 0;
	background: #fff;
	width: 100%;
	height: 100%;
}

.onekey-fixed.forbid {
	z-index: 100;
	position: fixed;
	top: auto;
	bottom: 68px;
	left: 9%;
	right: 0;
	background: rgba(0, 0, 0, 0.7);
	width: 82%;
	height: 43px;
	border-radius: 25px;
	color: #ffffff;
}
.onekey-login-title.forbid {
	text-align: center;
	padding-bottom: 3px;
	font-size: 14px;
	font-weight: normal;
	line-height: 30px;
	color: white;
}
</style><style>#login_mask {
  background: #000;
  opacity: 0.5;
  filter: alpha(opacity=50);
  position: fixed;
  /*fixed好像在哪个IE上有BUG，先用用*/
  left: 0;
  top: 0;
  z-index: 999;
  height: 100%;
}

#login_iframe_container {
  position: fixed;
  width: 550px;
  height: 360px;
  z-index: 1020;
  background-color: #ffffff;
}

@media screen and (max-width: 828px) {
  #login_iframe_container {
    top: 50% !important;
    left: 50% !important;
    transform: translate(-50%, -50%);
  }
}

#login_iframe_container.new-login {
  width: 550px;
  height: 360px;
  background-image: url(//web.archive.org/web/20221025113757/https://hhy.sogoucdn.com/js/common/hhy/background_2a4a8a6.png);
}

#login_iframe_container.new-login.no-bg {
  background: #fff;
}

#login_iframe_container.new-login .login-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 30px;
  letter-spacing: 0.19px;
  color: #ffffff;
  margin-top: 62px;
}
#login_iframe_container.new-login .forbid-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 24px;
  letter-spacing: 0.19px;
  color: #333333;
  margin-top: 150px;
}

#login_iframe_container.new-login.no-bg .login-title {
  color: #333333;
}

#login_iframe_container.new-login .login-subtitle {
  width: 100%;
  height: 18px;
  line-height: 18px;
  font-size: 13px;
  letter-spacing: 0.08px;
  color: #ffffff;
  text-align: center;
  margin-top: 9px;
  margin-bottom: 43px;
}

#login_iframe_container.new-login.no-bg .login-subtitle {
  color: #999999;
}

#login_iframe_container.new-login .login-subtitle::before {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: -5px;
}

#login_iframe_container.new-login .login-subtitle::after {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: 5px;
}

#login_iframe_container.new-login.no-bg .login-subtitle::before {
  background-color: #999999;
}

#login_iframe_container.new-login.no-bg .login-subtitle::after {
  background-color: #999999;
}

#login_iframe_container.new-login .close-btn {
  position: absolute;
  top: 20px;
  right: 20px;
  width: 12px;
  height: 12px;
  background: url(//web.archive.org/web/20221025113757/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -59px -10px;
  background-size: 81px 91px;
  cursor: pointer;
}

#login_iframe_container.new-login .login-btn {
  width: 220px;
  height: 47px;
  border-radius: 24px;
  border: solid 1px #dddddd;
  background-color: #ffffff;
  margin: 0 auto;
  margin-top: 28px;
  position: relative;
  display: block;
}

#login_iframe_container.new-login .login-btn .login-icon {
  position: absolute;
}

#login_iframe_container.new-login .login-btn .login-text {
  width: 61px;
  height: 47px;
  line-height: 47px;
  vertical-align: middle;
  font-size: 15px;
  letter-spacing: 0.1px;
  color: #666666;
  position: absolute;
  right: 62px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-icon {
  width: 22px;
  height: 27px;
  top: 10px;
  left: 67px;
  background: url(//web.archive.org/web/20221025113757/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -54px;
  background-size: 81px 91px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-text {
  right: 59px;
}

#login_iframe_container.new-login .login-btn.wechat-btn .login-icon {
  width: 29px;
  height: 24px;
  top: 12px;
  left: 62px;
  background: url(//web.archive.org/web/20221025113757/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -10px;
  background-size: 81px 91px;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style></head><body class=""><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
</style>
<script>__wm.rw(0);</script>
<div id="wm-ipp-base" lang="en" style="display: block; direction: ltr;">
</div><div id="wm-ipp-print">The Wayback Machine - https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm</div>
<script type="text/javascript">//<![CDATA[
__wm.bt(675,27,25,2,"web","https://baike.sogou.com/kexue/d11080.htm","20221025090628",1996,"/_static/",["/_static/css/banner-styles.css?v=S1zqJCYt","/_static/css/iconochive.css?v=qtvMKcIJ"], false);
  __wm.rw(1);
//]]></script>
<!-- END WAYBACK TOOLBAR INSERT --><script>window._gtag=window._gtag||{};window._gtag.shouldGrayed = false;if ('377a14737a584bacabc1467082a5beb8') window._gtag.traceId = '377a14737a584bacabc1467082a5beb8';if ({"illegality":true}) window.userInfo = {"illegality":true};</script><div class="topnavbox"><ul class="topnav"><li><a href="https://web.archive.org/web/20221025090628/https://www.sogou.com/web?query=">网页</a></li><li><a href="https://web.archive.org/web/20221025090628/https://weixin.sogou.com/weixin?p=75351201">微信</a></li><li><a href="https://web.archive.org/web/20221025090628/https://zhihu.sogou.com/zhihu?p=75351218">知乎</a></li><li><a href="https://web.archive.org/web/20221025090628/https://pic.sogou.com/pics?query=">图片</a></li><li><a href="https://web.archive.org/web/20221025090628/https://v.sogou.com/v?query=">视频</a></li><li><a href="https://web.archive.org/web/20221025090628/https://mingyi.sogou.com/">医疗</a></li><li class="cur"><strong>科学</strong></li><li><a href="https://web.archive.org/web/20221025090628/https://hanyu.sogou.com/">汉语</a></li><li><a href="https://web.archive.org/web/20221025090628/https://wenwen.sogou.com/">问问</a></li><li><a href="https://web.archive.org/web/20221025090628/https://www.sogou.com/docs/more.htm">更多<span class="topraquo">»</span></a></li></ul></div><div id="header"><div class="header-wrap"><a class="header-logo" href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue"></a><div class="header-search"><div class="querybox" id="suggBox"><form><input id="searchInput" class="query" type="text" placeholder="搜科学领域专业百科词条" name="query" autocomplete="off" value=""><a href="javascript:;" class="query-search"></a></form></div></div><div class="header-rgt"><span class="btn-header-rgt btn-edit" id="editLemma">创建</span><div class="header-user no-login"></div></div></div></div><div class="fixed-placeholder" style="visibility:none"></div><div id="container" class=""><div class="content lemma-level1"><div class="detail-title" id="abstract-title"><h1>选择性COX2抑制剂</h1><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#!" class="detail-edit">编辑</a></div><div class="section_content" data-id="54263825834238219"><div><p>选择性COX2抑制剂又称选择性环氧合酶-2抑制剂，是一种非甾体类抗炎药，直接作用于环氧合酶-2，环氧合酶-2是一种可诱导炎症和疼痛的酶。环氧合酶-2的靶向选择性降低了消化性溃疡形成的风险，是塞来昔布，罗非考昔等该类其他药物的主要特征。</p>
<p>在几种环氧合酶-2抑制剂被批准上市后，临床试验数据显示，环氧化酶-2抑制剂导致心脏病发作和中风的风险显著增加，其中一些药物的风险比其他药物更大。因为这些顾虑，罗非昔布 (俗称万络)于2004年退出市场，且塞来昔布和传统的非甾体抗炎药在其标签上也做出了黑框警告。许多环氧合酶-2特异性抑制剂已经从美国市场上退出。截至2011年12月，只有西乐葆(通用名为塞来昔布)仍可在美国购买。</p></div></div><div id="catalog"><h2 class="title2">目录<a href="javascript:" class="detail-edit">编辑</a></h2><div class="catalog_wrap" style=""><ul class="catalog_list col2"><li><span class="order">1</span><a href="javascript:" data-level="1" data-id="14996304723706381">医疗用途</a></li><li class="secondary_catalog"><span>1.1 </span><a href="javascript:" data-id="14996304723706381">癌症</a></li><li class="secondary_catalog"><span>1.2 </span><a href="javascript:" data-id="14996304723706381">神经精神障碍</a></li><li class="secondary_catalog"><span>1.3 </span><a href="javascript:" data-id="14996304723706381">其他目标</a></li><li class="secondary_catalog"><span>1.4 </span><a href="javascript:" data-id="14996304723706381">不利影响</a></li><li><span class="order">2</span><a href="javascript:" data-level="1" data-id="14996304723706382">研究</a></li></ul><ul class="catalog_list col2"><li class="secondary_catalog"><span>2.1 </span><a href="javascript:" data-id="14996304723706382">研究历史</a></li><li class="secondary_catalog"><span>2.2 </span><a href="javascript:" data-id="14996304723706382">学术不端</a></li><li class="secondary_catalog"><span>2.3 </span><a href="javascript:" data-id="14996304723706382"><b>早期环氧合酶-2抑制药物</b></a></li><li class="secondary_catalog"><span>2.4 </span><a href="javascript:" data-id="14996304723706382">神经母细胞瘤</a></li><li><span class="order">3</span><a href="javascript:" data-level="1" data-id="references">参考文献</a></li></ul></div></div><div id="paragraphs"><div><div id="par_14996304723706381"><h2 class="title">1 医疗用途<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>一些环氧合酶-2抑制剂单剂量用于治疗手术后疼痛。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_1" class="kx_ref">[1]</a></sup><sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_2" class="kx_ref">[2]</a></sup> </p><p>依托考昔似乎不如其他止痛药更好。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_3" class="kx_ref">[3]</a></sup> 塞来昔布似乎和布洛芬一样有用。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_4" class="kx_ref">[4]</a></sup> </p><p>非甾体抗炎药通常用于治疗急性痛风发作。环氧合酶-2抑制剂似乎和非选择性非甾体抗炎药一样有效。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_5" class="kx_ref">[5]</a></sup> 但是它们还没有与秋水仙碱或糖皮质激素等其他治疗方案进行比较。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_5" class="kx_ref">[5]</a></sup><sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_6" class="kx_ref">[6]</a></sup> </p><p></p><h3>1.1 <span>癌症</span></h3><p></p><p>环氧合酶-2似乎与癌症和肠道异常生长有关。环氧合酶抑制剂已被证明能减少癌症和癌前病变的发生。国家癌症研究所对环氧合酶-2和癌症进行了一些研究。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_7" class="kx_ref">[7]</a></sup>美国食品药品监督管理局已经批准西乐葆治疗家族性腺瘤息肉病(FAP)。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_8" class="kx_ref">[8]</a></sup>目前正在研究的乳腺癌药物中，环氧合酶-2<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_9" class="kx_ref">[9]</a></sup>似乎是有效的。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_10" class="kx_ref">[10]</a></sup> </p><p></p><h3>1.2 <span>神经精神障碍</span></h3><p></p><p>环氧合酶-2抑制剂已被发现能有效抑制精神疾病中的炎性神经退行性通路，在重度抑郁症和精神分裂症的试验中取得了良好的治疗效果。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_11" class="kx_ref">[11]</a></sup> </p><p></p><h3>1.3 <span>其他目标</span></h3><p></p><p>抑制环氧合酶-2对于选择性环氧合酶-2抑制剂塞来昔布的抗炎和镇痛功能至关重要。然而，关于这种药物治疗晚期癌症的前景，目前还不清楚环氧合酶-2的抑制是否起主导作用，这已成为一个有争议和深入研究的问题。近年来，发现了一些其他的细胞内成分(除了环氧化酶-2之外)，在环氧合酶-2不存在的情况下，这些成分似乎对调节塞来昔布的抗癌作用很重要。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_12" class="kx_ref">[12]</a></sup>此外，最近一项针对各种恶性肿瘤细胞的研究表明，塞来昔布可以抑制这些细胞的生长，尽管其中一些癌细胞甚至不含环氧合酶-2。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_13" class="kx_ref">[13]</a></sup> </p><p>除了环氧合酶-2外，其他靶点对塞来昔布的抗癌作用也很重要，这一观点得到了来自化学修饰版本塞来昔布的研究的进一步支持。几十种塞来昔布类似物的化学结构发生了微小的变化。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_14" class="kx_ref">[14]</a></sup> 其中一些类似物保留了环氧合酶-2抑制活性，而许多其他类似物则没有。然而，当研究所有这些化合物在细胞培养物中杀死肿瘤细胞的能力时，结果发现抗肿瘤效力根本不取决于各自的化合物是否能抑制环氧合酶-2，这表明抑制环氧合酶-2对抗癌效果不是必需的。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_14" class="kx_ref">[14]</a></sup><sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_15" class="kx_ref">[15]</a></sup> 这些化合物中的一种，2，5-二甲基塞来昔布完全缺乏抑制环氧化酶-2的能力，实际上显示出比塞来昔布本身更强的抗癌活性<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_16" class="kx_ref">[16]</a></sup> 并且这种抗癌作用也可以在高耐药性肿瘤细胞<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_17" class="kx_ref">[17]</a></sup>和各种动物肿瘤模型中得到证实。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_18" class="kx_ref">[18]</a></sup><sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_19" class="kx_ref">[19]</a></sup> </p><p></p><h3>1.4 <span>不利影响</span></h3><p></p><p>临床试验数据分析显示，与安慰剂相比，环氧合酶-2抑制剂导致的血管事件发生率显著增加；“血管事件”是指非致命性心肌梗塞（MI）或心脏病发作、非致命性中风以及由血管事件如心肌梗塞或中风导致的死亡。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_20" class="kx_ref">[20]</a></sup><sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_21" class="kx_ref">[21]</a></sup> 这些结果导致默克公司于2004年9月自愿从市场上召回(罗非昔布)，并向监管机构发出塞来昔布标签上的黑框警告。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_20" class="kx_ref">[20]</a></sup>传统非甾体抗炎药也被发现有心血管风险，导致类似的黑框警告。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_20" class="kx_ref">[20]</a></sup> </p><p>导致心血管问题的原因成为持续深入研究的课题。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_22" class="kx_ref">[22]</a></sup>截至2012年，研究结果趋于一致，认为即造成心血管副作用最有可能原因是由于血管中环氧合酶-2的抑制，这导致血管中前列环素的产生减少。前列环素通常防止血小板聚集和血管收缩，因此其抑制作用会导致血栓形成和高血压。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_22" class="kx_ref">[22]</a></sup> </p></div></div><div id="par_14996304723706382"><h2 class="title">2 研究<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><h3>2.1 <span>研究历史</span></h3><p></p><p>环氧合酶-2是由杨百翰大学研究员丹尼尔·西蒙斯（Daniel Simmons）于1988年发现。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_23" class="kx_ref">[23]</a></sup> 1991年发表的一项发现是，加州大学洛杉矶分校科学家哈维·赫希曼博士克隆了小鼠环氧合酶-2基因。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_24" class="kx_ref">[24]</a></sup> </p><p>导致环氧化酶-2抑制剂发现的基础研究已经至少涉及两起诉讼。杨百翰大学起诉辉瑞公司，指控其违反了西蒙斯博士在杨百翰大学工作时与该公司的关系。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_25" class="kx_ref">[25]</a></sup><sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_26" class="kx_ref">[26]</a></sup> 2012年4月达成和解，辉瑞同意支付4.5亿美元。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_27" class="kx_ref">[27]</a></sup><sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_28" class="kx_ref">[28]</a></sup> 另一项诉讼基于美国专利，罗切斯特大学拥有的美国专利号为6048850，<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_29" class="kx_ref">[29]</a></sup>该专利声称有一种通过选择性抑制环氧化酶-2来治疗疼痛而不引起胃肠不适的方法。当专利发布时，该大学起诉塞尔(后来的辉瑞公司)，案件名为罗切斯特大学诉塞尔公司，358 F.3d 916(联邦巡回法院，2004年)。法院在2004年作出了有利于塞尔的裁决，基本上认为该大学虽然声称有一种方法，要求能够抑制环氧化酶-2的化合物，但没有提供书面描述，因此该专利无效。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_30" class="kx_ref">[30]</a></sup><sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_31" class="kx_ref">[31]</a></sup> </p><p>在寻找前列腺素副作用的特定抑制剂而不产生积极效应的过程中，发现前列腺素确实可以分为两大类，根据参与其生物合成的特定酶环氧合酶的结构，这两大类可以粗略地被认为是“好的前列腺素”和“坏的前列腺素”。</p><p>合成涉及环氧酶-1或环氧合酶-1的前列腺素负责胃肠道的维持和保护，而合成涉及环氧酶-2或环氧合酶-2的前列腺素负责炎症和疼痛。</p><p>现有的非甾体抗炎药对环氧合酶-2和环氧合酶-1的相对特异性不同；虽然阿司匹林和布洛芬抑制环氧化酶-2和环氧化酶-1酶，但其他非甾体抗炎药似乎具有部分环氧化酶-2特异性，特别是美洛昔康（莫比可）。阿司匹林抑制环氧合酶-1的能力是环氧合酶-2的大约170倍。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_32" class="kx_ref">[32]</a></sup>对美洛昔康进行每日7.5毫克为期23天的的研究发现，胃损伤水平与使用安慰剂相似，美洛昔康每日15毫克的损伤水平低于其他非甾体抗炎药；然而，在临床实践中，美洛昔康仍然会引起一些溃疡并发症。</p><p>伐地考昔和罗非考昔在抑制环氧化酶-2的效力上约为抑制环氧化酶-1的300倍，但对心脏毒性太大，表明有可能缓解疼痛和炎症，而不会刺激胃肠道，并有望对那些之前曾经历副作用或有可能导致此类并发症的共病患者有所裨益。塞来昔布抑制环氧化酶-2的效力大约是抑制环氧化酶-1的30倍，依托考昔的抑制环氧化酶-2效力是抑制环氧化酶-1的106倍。</p><p></p><h3>2.2 <span>学术不端</span></h3><p></p><p>1996年至2009年间，麻醉师斯科特·鲁本(Scott Reuben)进行环氧化酶-2抑制剂临床应用研究，即环氧合酶-2抑制剂与加巴喷丁或普瑞巴林联合使用，用以预防和治疗术后疼痛，该研究在2009年被发现存在学术造假的问题。鲁本供认不讳，为此支付罚款，在监狱服刑六个月，同时医疗执照被撤销。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_33" class="kx_ref">[33]</a></sup>2009年基于循证医学的荟萃分析文章的综述发现，尽管当鲁本研究被删除时，一些综述不再有效，但其中大多数的研究综述结论保持不变。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_34" class="kx_ref">[34]</a></sup>该综述发现，鲁本研究中需要重新审查的是“脊柱手术后，环氧合酶抑制剂对骨愈合没有不利影响，预先服用环氧合酶抑制剂后有长期的有益结果，包括据称手术后慢性疼痛的发生率降低，以及酮咯酸或可乐定加入局部麻醉剂后用于静脉局部麻醉时的镇痛效果。”<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_34" class="kx_ref">[34]</a></sup> </p><p></p><h3>2.3 <span>早期环氧合酶-2抑制药物</span></h3><p></p><p>塞来昔布(以及塞来昔布的其他品牌)于1999年推出，并迅速成为美国处方常用新药。到2000年10月，它在美国的年销售量超过1亿张处方，达到30亿美元，而且还在上升。仅西乐葆的销售额在2001年就达到了31亿美元。西班牙的一项研究发现，在2000年1月至2001年6月期间，7%的非甾体抗炎药处方和29%的非甾体抗炎药支出用于环氧合酶-2抑制剂。在研究期间，环氧合酶-2抑制剂从专科医生开出的总非甾体抗炎药的10.03%上升到29.79%，从初级保健医生开出的非甾体抗炎药的1.52%上升到10.78%(98.23%的非甾体抗炎药和94.61%的环氧合酶-2抑制剂由初级保健医生开出)。对于专科医师而言，罗非昔布和塞来昔布在最常用的非甾体抗炎药中分别位居第三和第五，但在成本上却分别位居第一和第二；对于初级保健医生来说，他们是第九和第十二位最常开的非甾体抗炎药，费用也是第一和第四位。</p><p>塞来昔布和万络迅速被医生广泛接受的原因两项大型试验的发表，即美国医学会杂志的塞来昔布长期应用于关节炎安全性研究<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_35" class="kx_ref">[35]</a></sup>和万络胃肠道预后研究(VIGOR)。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_36" class="kx_ref">[36]</a></sup>该实验后来被证明是基于错误数据的研究，万络最终退出了市场。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_37" class="kx_ref">[37]</a></sup> </p><p><strong><b>万络胃肠道预后研究与出版争议</b></strong></p><p>万络胃肠道预后结果研究（VIGOR）试验，“是默克公司罗非昔布的杰作”，<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_37" class="kx_ref">[37]</a></sup>它是医学期刊伦理争议的中心。万络胃肠道预后结果研究，是一项由 8000多名患者随机接受萘普生或罗非昔布(Vioxx)治疗的研究，其中一种环氧合酶-2抑制剂，默克希望它能减少胃肠道副作用。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_37" class="kx_ref">[37]</a></sup>两份出版物都得出结论，环氧合酶-2特异性非甾体抗炎药与胃肠道副作用显著减少有关。在为期6个月的类试验中，比较西乐葆800毫克/天与布洛芬2400毫克/天和双氯芬酸150毫克/天治疗骨关节炎或类风湿性关节炎，西乐葆与明显较少的上消化道并发症相关(0.44%vs.1.27%，P=0.04)，未服用阿司匹林而进行心血管预防的患者心血管事件发生率无显著性差异。</p><p>万络胃肠道预后结果研究试验结果发表在2000年的《新英格兰医学杂志》上，<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_38" class="kx_ref">[38]</a></sup>庞巴迪和他的研究团队声称“服用罗非昔布的患者心肌梗死发生率(0.4%)高于服用萘普生的患者(0.1%)”，“服用萘普生的患者出现了121种副作用，而服用罗非昔布的患者出现了56种副作用”，这是“默克的惊人结果”，这“促成了罗非昔布的大量销售”<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_37" class="kx_ref">[37]</a></sup>。默克公司的科学家错误地将这一发现解释为萘普生的保护作用，告诉美国FDA心脏病发作的不同“主要是”由于“主要是由于”这种保护作用。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_39" class="kx_ref">[39]</a></sup>[39]2001年9月，美国食品食品药品监督管理局(FDA)给默克公司首席执行官发了一封警告信，称“你们的促销活动歪曲了这样一个事实，即在万络胃肠道预后研究研究中，观察到服用万络的患者心肌梗塞(MIs)比服用对照非甾体抗炎药萘普生(NSAID)的患者增加了4到5倍。”<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_40" class="kx_ref">[40]</a></sup>这导致在2002年4月在万络标签上引入了关于心血管事件(心脏病发作和中风)风险增加的警告。到2005年，《新英格兰医学杂志》发表了一篇社论，指责庞巴迪等人故意隐瞒数据。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_41" class="kx_ref">[41]</a></sup> </p><p>多伦多大学风湿病学家克莱尔·庞巴迪(Claire Bombardier)博士曾声称，VIGOR试验测试导致万络剂量为50毫克/天与萘普生治疗类风湿性关节炎相比，万络将症状性溃疡和临床上消化道事件(穿孔、阻塞和出血)的风险降低至54%，又从3%降至1.4%，将复杂上消化道事件(复杂穿孔、阻塞和上消化道出血)的风险降低至57%，从胃肠道任何部位出血的风险降至62%。这些出版物创造出了一个巨大的市场效应；根据国际监测系统健康中心的数据，万络是2000年广告宣传最多的处方药，西乐葆是第七名。</p><p></p><h3>2.4 <span>神经母细胞瘤</span></h3><p></p><p>交感神经系统的小肿瘤(神经母细胞瘤)似乎有异常水平的环氧合酶-2表达。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_42" class="kx_ref">[42]</a></sup>这些研究报告了环氧合酶-2的过度表达对肿瘤抑制因子p53有不利影响。p53是通常在细胞浆中发现的凋亡转录因子。当细胞的脱氧核糖核酸受损无法修复时，p53被转移到细胞核，在那里它促进p53介导的凋亡。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_43" class="kx_ref">[43]</a></sup>环氧化酶-2的两种代谢物，前列腺素A2 (PGA2)和A1 (PGA1)，当它们大量存在时，与胞质溶胶中的p53结合并抑制其进入细胞核的能力。这基本上将p53隔离在细胞浆中并防止细胞凋亡。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_43" class="kx_ref">[43]</a></sup>昔布类，如塞来昔布，通过选择性抑制过表达的环氧合酶-2，允许p53正常工作。功能性p53允许脱氧核糖核酸损伤的神经母细胞瘤细胞通过凋亡自杀，阻止肿瘤生长。</p><p>环氧合酶-2上调也与E3泛素连接酶HDM2的磷酸化和激活有关，HDM 2是一种通过泛素化介导p53连接和标记破坏的蛋白质。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_43" class="kx_ref">[43]</a></sup>这种神经母细胞瘤HDM2过度活跃的机制尚不清楚。研究表明，环氧合酶-2抑制剂阻止HDM2的磷酸化，阻止其活化。在体外，环氧合酶-2抑制剂的使用降低了神经母细胞瘤细胞中活性HDM2的水平。环氧合酶-2抑制剂如何阻断HDM2磷酸化的确切过程尚不清楚，但这种介导的活性HDM2浓度水平的降低恢复了细胞p53水平。用环氧合酶-2抑制剂治疗后，恢复的p53功能允许受损伤的神经母细胞瘤细胞通过凋亡而自杀，从而减少肿瘤的生长。<sup><a href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/d11080.htm#quote_43" class="kx_ref">[43]</a></sup> </p></div></div></div></div><div id="references"><h2 class="title" id="par_references">参考文献</h2><ul class="references"><li id="quote_1"><span class="references-num">[1]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Tirunagari SK, Derry S, Moore RA, McQuay HJ (2009). "Single dose oral etodolac for acute postoperative pain in adults". The Cochrane Database of Systematic Reviews (3): CD007357. doi:10.1002/14651858.CD007357.pub2. PMC 4164827. PMID 19588426..</span></p></li><li id="quote_2"><span class="references-num">[2]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Bulley S, Derry S, Moore RA, McQuay HJ (2009). "Single dose oral rofecoxib for acute postoperative pain in adults". The Cochrane Database of Systematic Reviews (4): CD004604. doi:10.1002/14651858.CD004604.pub3. PMC 4171390. PMID 19821329..</span></p></li><li id="quote_3"><span class="references-num">[3]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Clarke R, Derry S, Moore RA (May 8, 2014). "Single dose oral etoricoxib for acute postoperative pain in adults". The Cochrane Database of Systematic Reviews. 5 (5): CD004309. doi:10.1002/14651858.CD004309.pub4. PMID 24809657..</span></p></li><li id="quote_4"><span class="references-num">[4]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Derry S, Moore RA (Oct 22, 2013). "Single dose oral celecoxib for acute postoperative pain in adults". The Cochrane Database of Systematic Reviews. 10 (10): CD004233. doi:10.1002/14651858.CD004233.pub4. PMC 4161494. PMID 24150982..</span></p></li><li id="quote_5"><span class="references-num">[5]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landewé RB (16 September 2014). "Non-steroidal anti-inflammatory drugs for acute gout". The Cochrane Database of Systematic Reviews. 9 (9): CD010120. doi:10.1002/14651858.CD010120.pub2. PMID 25225849..</span></p></li><li id="quote_6"><span class="references-num">[6]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">van Durme CM, Wechalekar MD, Landewé RB (Jun 2015). "Nonsteroidal anti-inflammatory drugs for treatment of acute gout". JAMA. 313 (22): 2276–7. doi:10.1001/jama.2015.1881. PMID 26057289..</span></p></li><li id="quote_7"><span class="references-num">[7]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"COX-2 Inhibitors and Cancer". Fact Sheet. United States National Cancer Institute. Archived from the original on May 9, 2008..</span></p></li><li id="quote_8"><span class="references-num">[8]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Archived copy". Archived from the original on May 10, 2008. Retrieved May 8, 2008.CS1 maint: Archived copy as title (link).</span></p></li><li id="quote_9"><span class="references-num">[9]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Chow LW, Loo WT, Toi M (Oct 2005). "Current directions for COX-2 inhibition in breast cancer". Biomedicine &amp; Pharmacotherapy. 59 Suppl 2: S281–4. doi:10.1016/S0753-3322(05)80046-0. PMID 16507393..</span></p></li><li id="quote_10"><span class="references-num">[10]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, Gupta K (Dec 2007). "COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia". British Journal of Cancer. 97 (11): 1523–31. doi:10.1038/sj.bjc.6604057. PMC 2360252. PMID 17971769..</span></p></li><li id="quote_11"><span class="references-num">[11]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Müller N (Jan 2010). "COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence". Current Opinion in Investigational Drugs. 11 (1): 31–42. PMID 20047157..</span></p></li><li id="quote_12"><span class="references-num">[12]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Schönthal AH (Dec 2007). "Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy". British Journal of Cancer. 97 (11): 1465–8. doi:10.1038/sj.bjc.6604049. PMC 2360267. PMID 17955049..</span></p></li><li id="quote_13"><span class="references-num">[13]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Chuang HC, Kardosh A, Gaffney KJ, Petasis NA, Schönthal AH (2008). "COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro". Molecular Cancer. 7: 38. doi:10.1186/1476-4598-7-38. PMC 2396175. PMID 18485224..</span></p></li><li id="quote_14"><span class="references-num">[14]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS (Dec 2002). "Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents". Journal of the National Cancer Institute. 94 (23): 1745–57. doi:10.1093/jnci/94.23.1745. PMID 12464646..</span></p></li><li id="quote_15"><span class="references-num">[15]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Schönthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA (Feb 2008). "Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs". Expert Opinion on Investigational Drugs. 17 (2): 197–208. doi:10.1517/13543784.17.2.197. PMID 18230053..</span></p></li><li id="quote_16"><span class="references-num">[16]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Schönthal AH (2006). "Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy". Neurosurgical Focus. 20 (4): E21. doi:10.3171/foc.2006.20.4.14. PMID 16709027..</span></p></li><li id="quote_17"><span class="references-num">[17]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Kardosh A, Soriano N, Liu YT, Uddin J, Petasis NA, Hofman FM, Chen TC, Schönthal AH (Dec 2005). "Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib". Blood. 106 (13): 4330–8. doi:10.1182/blood-2005-07-2819. PMID 16123214..</span></p></li><li id="quote_18"><span class="references-num">[18]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Pyrko P, Kardosh A, Liu YT, Soriano N, Xiong W, Chow RH, Uddin J, Petasis NA, Mircheff AK, Farley RA, Louie SG, Chen TC, Schönthal AH (Apr 2007). "Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib". Molecular Cancer Therapeutics. 6 (4): 1262–75. doi:10.1158/1535-7163.MCT-06-0629. PMID 17431104..</span></p></li><li id="quote_19"><span class="references-num">[19]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Kardosh A, Wang W, Uddin J, Petasis NA, Hofman FM, Chen TC, Schönthal AH (May 2005). "Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo". Cancer Biology &amp; Therapy. 4 (5): 571–82. doi:10.4161/cbt.4.5.1699. PMID 15846081..</span></p></li><li id="quote_20"><span class="references-num">[20]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA (Mar 2007). "Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association". Circulation. 115 (12): 1634–42. doi:10.1161/CIRCULATIONAHA.106.181424. PMID 17325246..</span></p></li><li id="quote_21"><span class="references-num">[21]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C (Jun 2006). "Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials". BMJ. 332 (7553): 1302–8. doi:10.1136/bmj.332.7553.1302. PMC 1473048. PMID 16740558..</span></p></li><li id="quote_22"><span class="references-num">[22]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Cannon CP, Cannon PJ (Jun 2012). "Physiology. COX-2 inhibitors and cardiovascular risk". Science. 336 (6087): 1386–7. Bibcode:2012Sci...336.1386C. doi:10.1126/science.1224398. PMID 22700906..</span></p></li><li id="quote_23"><span class="references-num">[23]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (Apr 1991). "Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing". Proceedings of the National Academy of Sciences of the United States of America. 88 (7): 2692–6. Bibcode:1991PNAS...88.2692X. doi:10.1073/pnas.88.7.2692. PMC 51304. PMID 1849272..</span></p></li><li id="quote_24"><span class="references-num">[24]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (Jul 1991). "TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue". The Journal of Biological Chemistry. 266 (20): 12866–72. PMID 1712772..</span></p></li><li id="quote_25"><span class="references-num">[25]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Yajnik J (2006-10-27). "University sues Pfizer over COX-2 research". The Scientist. Retrieved 2010-11-11..</span></p></li><li id="quote_26"><span class="references-num">[26]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Tom Harvey (2010-09-21). "BYU spices up Celebrex lawsuit against Pfizer". The Salt Lake Tribune. Retrieved 2011-02-28..</span></p></li><li id="quote_27"><span class="references-num">[27]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Tom Harvey (May 1, 2012). "Pfizer, BYU settle Celebrex lawsuit for $450M". The Salt Lake Tribune..</span></p></li><li id="quote_28"><span class="references-num">[28]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Associated Press, May 1, 2012 Pfizer Settles B.Y.U. Lawsuit Over Development of Celebrex.</span></p></li><li id="quote_29"><span class="references-num">[29]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">US Patent 6048850,.</span></p></li><li id="quote_30"><span class="references-num">[30]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Publications: Hodgson Russ LLP". Hodgsonruss.com. Retrieved 2015-05-23..</span></p></li><li id="quote_31"><span class="references-num">[31]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Ranjana Kadle (2004) CAFC Court Decision Reach-Through Claims Declared Invalid Archived 2013-07-21 at the Wayback Machine.</span></p></li><li id="quote_32"><span class="references-num">[32]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Awtry EH, Loscalzo J (Mar 2000). "Aspirin". Circulation. 101 (10): 1206–18. doi:10.1161/01.cir.101.10.1206. PMID 10715270..</span></p></li><li id="quote_33"><span class="references-num">[33]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">A Medical Madoff: Anesthesiologist Faked Data in 21 Studies, Scientific American, March 10, 2009.</span></p></li><li id="quote_34"><span class="references-num">[34]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Marret E, Elia N, Dahl JB, McQuay HJ, Møiniche S, Moore RA, Straube S, Tramèr MR (Dec 2009). "Susceptibility to fraud in systematic reviews: lessons from the Reuben case". Anesthesiology. 111 (6): 1279–89. doi:10.1097/ALN.0b013e3181c14c3d. PMID 19934873..</span></p></li><li id="quote_35"><span class="references-num">[35]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (Sep 2000). "Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study". JAMA. 284 (10): 1247–55. doi:10.1001/jama.284.10.1247. PMID 10979111..</span></p></li><li id="quote_36"><span class="references-num">[36]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ (Nov 2000). "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group". The New England Journal of Medicine. 343 (21): 1520–8, 2 p following 1528. doi:10.1056/NEJM200011233432103. PMID 11087881..</span></p></li><li id="quote_37"><span class="references-num">[37]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Smith R (2006). "Lapses at the new England journal of medicine". Journal of the Royal Society of Medicine. 99 (8): 380–2. doi:10.1258/jrsm.99.8.380. PMC 1533509. PMID 16893926..</span></p></li><li id="quote_38"><span class="references-num">[38]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Bombardier C.; Laine L.; Reicin A. (2000). "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis". 343 (1520). New England Journal of Medicine..</span></p></li><li id="quote_39"><span class="references-num">[39]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"NAME OF DRUG: Rofecoxib (MK-0966) : Memorandum" (PDF). Fda.gov. Retrieved 4 January 2015..</span></p></li><li id="quote_40"><span class="references-num">[40]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">"Warning Letter" (PDF). Fda.gov. Retrieved 4 January 2015..</span></p></li><li id="quote_41"><span class="references-num">[41]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Curfman GD, Morrissey S, Drazen JM (Dec 2005). "Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8". The New England Journal of Medicine. 353 (26): 2813–4. doi:10.1056/NEJMe058314. PMID 16339408..</span></p></li><li id="quote_42"><span class="references-num">[42]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Johnsen JI, Lindskog M, Ponthan F, Pettersen I, Elfman L, Orrego A, Sveinbjörnsson B, Kogner P (Oct 2004). "Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo". Cancer Research. 64 (20): 7210–5. doi:10.1158/0008-5472.CAN-04-1795. PMID 15492235..</span></p></li><li id="quote_43"><span class="references-num">[43]</span><p><a class="ref-back-btn">^</a><span data-url="" class="">Lau L, Hansford LM, Cheng LS, Hang M, Baruchel S, Kaplan DR, Irwin MS (Mar 2007). "Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma". Oncogene. 26 (13): 1920–31. doi:10.1038/sj.onc.1209981. PMID 16983334..</span></p></li></ul></div><div class="read-num">阅读 <!-- -->1.1<!-- -->w</div></div><div class="right-side" id="rightSide"><div class="side" id="lemma-side"><div class="side-title">版本记录</div><ul class="side-lst"><li><p class="side-lst-txt">暂无</p></li></ul><div class="user-card userCard"></div></div><div class="side"><div class="side-event"></div></div></div></div><div class="footer-box"><div id="footer"><div class="footer-logo-wrap"><div class="footer-logo"></div><div class="footer-logo-text">知识·传播·科普</div></div><div class="footer-info">本网站内容采用<a target="_blank" href="https://web.archive.org/web/20221025090628/https://creativecommons.org/licenses/by-sa/3.0/deed.zh?tdsourcetag=s_pctim_aiomsg">CC-BY-SA 3.0</a>授权</div><div class="footer-btn-wrap"><a target="_blank" href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/help/#user_protocol">用户协议</a><a target="_blank" href="https://web.archive.org/web/20221025090628/http://www.sogou.com/docs/terms.htm?v=1">免责声明</a><a target="_blank" href="https://web.archive.org/web/20221025090628/http://corp.sogou.com/private.html">隐私政策</a><a target="_blank" href="https://web.archive.org/web/20221025090628/https://baike.sogou.com/kexue/intro.htm">关于我们</a></div></div></div><script>window.lemmaInfo ={"lemmaId":"11080","versionId":"54263825834238215","title":"选择性COX2抑制剂","subtitle":"","abstracts":{"paragraphId":"54263825834238219","title":"摘要","versionId":"54263825834238216","lemmaId":11080,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":82859321,"name":"━╋独特","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599639760,"comment":null,"dependVersionId":0,"contentType":2,"content":"<p>选择性COX2抑制剂又称选择性环氧合酶-2抑制剂，是一种非甾体类抗炎药，直接作用于环氧合酶-2，环氧合酶-2是一种可诱导炎症和疼痛的酶。环氧合酶-2的靶向选择性降低了消化性溃疡形成的风险，是塞来昔布，罗非考昔等该类其他药物的主要特征。</p>\n<p>在几种环氧合酶-2抑制剂被批准上市后，临床试验数据显示，环氧化酶-2抑制剂导致心脏病发作和中风的风险显著增加，其中一些药物的风险比其他药物更大。因为这些顾虑，罗非昔布 (俗称万络)于2004年退出市场，且塞来昔布和传统的非甾体抗炎药在其标签上也做出了黑框警告。许多环氧合酶-2特异性抑制剂已经从美国市场上退出。截至2011年12月，只有西乐葆(通用名为塞来昔布)仍可在美国购买。</p>","pics":null,"card":null,"references":[],"versionCount":0},"card":{"paragraphId":"0","title":"","versionId":"0","lemmaId":0,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":0,"comment":null,"dependVersionId":0,"contentType":0,"content":"","pics":null,"card":null,"references":null,"versionCount":0},"categories":[{"id":13,"name":"药学","parents":[]}],"creator":{"uid":10145103,"name":"柚子otto","pic":"https://web.archive.org/web/20221025090628/https://img02.sogoucdn.com/app/a/200698/1152_1152_1864088_20200427232849-1518843971.png","introduction":"","educations":[{"schoolName":"中国地质大学（北京）","major":"","degree":"本科","universityId":22,"universityLogo":"https://web.archive.org/web/20221025090628/https://img01.sogoucdn.com/app/a/200943/d3465c1c-6011-11e9-b353-fc4dd4f70029","majorLevel1":"理学","majorLevel2":"地理学","majorLevel3":"地图学与地理信息系统","majorLevel1Id":1,"majorLevel2Id":103,"majorLevel3Id":109,"state":"毕业","lab":"","researchField":""}],"jobs":[{"company":"搜狗","title":"产品经理"}],"works":null,"educationBrief":"中国地质大学（北京）","jobBrief":"产品经理","role":0,"roleName":null,"title":"中国地质大学（北京） · 地理学本科","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":139,"partnerIdCreateTime":1595844881,"partnerIdPoped":true},"createTime":1571038538,"editor":{"uid":10145103,"name":"柚子otto","pic":"https://web.archive.org/web/20221025090628/https://img02.sogoucdn.com/app/a/200698/1152_1152_1864088_20200427232849-1518843971.png","introduction":"","educations":[{"schoolName":"中国地质大学（北京）","major":"","degree":"本科","universityId":22,"universityLogo":"https://web.archive.org/web/20221025090628/https://img01.sogoucdn.com/app/a/200943/d3465c1c-6011-11e9-b353-fc4dd4f70029","majorLevel1":"理学","majorLevel2":"地理学","majorLevel3":"地图学与地理信息系统","majorLevel1Id":1,"majorLevel2Id":103,"majorLevel3Id":109,"state":"毕业","lab":"","researchField":""}],"jobs":[{"company":"搜狗","title":"产品经理"}],"works":null,"educationBrief":"中国地质大学（北京）","jobBrief":"产品经理","role":0,"roleName":null,"title":"中国地质大学（北京） · 地理学本科","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":139,"partnerIdCreateTime":1595844881,"partnerIdPoped":true},"editTime":1576234493,"state":1,"versionCount":1,"upNum":3,"downNum":0,"pics":[],"catalogs":[{"level":1,"title":"医疗用途","paragraphId":"14996304723706381","subCatalogs":[{"level":2,"title":"癌症","paragraphId":"14996304723706381","subCatalogs":null},{"level":2,"title":"神经精神障碍","paragraphId":"14996304723706381","subCatalogs":null},{"level":2,"title":"其他目标","paragraphId":"14996304723706381","subCatalogs":null},{"level":2,"title":"不利影响","paragraphId":"14996304723706381","subCatalogs":null}]},{"level":1,"title":"研究","paragraphId":"14996304723706382","subCatalogs":[{"level":2,"title":"研究历史","paragraphId":"14996304723706382","subCatalogs":null},{"level":2,"title":"学术不端","paragraphId":"14996304723706382","subCatalogs":null},{"level":2,"title":"<b>早期环氧合酶-2抑制药物</b>","paragraphId":"14996304723706382","subCatalogs":null},{"level":2,"title":"神经母细胞瘤","paragraphId":"14996304723706382","subCatalogs":null}]},{"level":1,"title":"参考文献","paragraphId":"-1","subCatalogs":null}],"paragraphs":[{"paragraphId":"14996304723706381","title":"医疗用途","versionId":"54263825834238217","lemmaId":11080,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":82859321,"name":"━╋独特","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599639760,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>一些环氧合酶-2抑制剂单剂量用于治疗手术后疼痛。<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup><sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup> </p><p>依托考昔似乎不如其他止痛药更好。<sup><a href=\"#quote_3\" class=\"kx_ref\">[3]</a></sup> 塞来昔布似乎和布洛芬一样有用。<sup><a href=\"#quote_4\" class=\"kx_ref\">[4]</a></sup> </p><p>非甾体抗炎药通常用于治疗急性痛风发作。环氧合酶-2抑制剂似乎和非选择性非甾体抗炎药一样有效。<sup><a href=\"#quote_5\" class=\"kx_ref\">[5]</a></sup> 但是它们还没有与秋水仙碱或糖皮质激素等其他治疗方案进行比较。<sup><a href=\"#quote_5\" class=\"kx_ref\">[5]</a></sup><sup><a href=\"#quote_6\" class=\"kx_ref\">[6]</a></sup> </p><p><h3>癌症</h3></p><p>环氧合酶-2似乎与癌症和肠道异常生长有关。环氧合酶抑制剂已被证明能减少癌症和癌前病变的发生。国家癌症研究所对环氧合酶-2和癌症进行了一些研究。<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup>美国食品药品监督管理局已经批准西乐葆治疗家族性腺瘤息肉病(FAP)。<sup><a href=\"#quote_8\" class=\"kx_ref\">[8]</a></sup>目前正在研究的乳腺癌药物中，环氧合酶-2<sup><a href=\"#quote_9\" class=\"kx_ref\">[9]</a></sup>似乎是有效的。<sup><a href=\"#quote_10\" class=\"kx_ref\">[10]</a></sup> </p><p><h3>神经精神障碍</h3></p><p>环氧合酶-2抑制剂已被发现能有效抑制精神疾病中的炎性神经退行性通路，在重度抑郁症和精神分裂症的试验中取得了良好的治疗效果。<sup><a href=\"#quote_11\" class=\"kx_ref\">[11]</a></sup> </p><p><h3>其他目标</h3></p><p>抑制环氧合酶-2对于选择性环氧合酶-2抑制剂塞来昔布的抗炎和镇痛功能至关重要。然而，关于这种药物治疗晚期癌症的前景，目前还不清楚环氧合酶-2的抑制是否起主导作用，这已成为一个有争议和深入研究的问题。近年来，发现了一些其他的细胞内成分(除了环氧化酶-2之外)，在环氧合酶-2不存在的情况下，这些成分似乎对调节塞来昔布的抗癌作用很重要。<sup><a href=\"#quote_12\" class=\"kx_ref\">[12]</a></sup>此外，最近一项针对各种恶性肿瘤细胞的研究表明，塞来昔布可以抑制这些细胞的生长，尽管其中一些癌细胞甚至不含环氧合酶-2。<sup><a href=\"#quote_13\" class=\"kx_ref\">[13]</a></sup> </p><p>除了环氧合酶-2外，其他靶点对塞来昔布的抗癌作用也很重要，这一观点得到了来自化学修饰版本塞来昔布的研究的进一步支持。几十种塞来昔布类似物的化学结构发生了微小的变化。<sup><a href=\"#quote_14\" class=\"kx_ref\">[14]</a></sup> 其中一些类似物保留了环氧合酶-2抑制活性，而许多其他类似物则没有。然而，当研究所有这些化合物在细胞培养物中杀死肿瘤细胞的能力时，结果发现抗肿瘤效力根本不取决于各自的化合物是否能抑制环氧合酶-2，这表明抑制环氧合酶-2对抗癌效果不是必需的。<sup><a href=\"#quote_14\" class=\"kx_ref\">[14]</a></sup><sup><a href=\"#quote_15\" class=\"kx_ref\">[15]</a></sup> 这些化合物中的一种，2，5-二甲基塞来昔布完全缺乏抑制环氧化酶-2的能力，实际上显示出比塞来昔布本身更强的抗癌活性<sup><a href=\"#quote_16\" class=\"kx_ref\">[16]</a></sup> 并且这种抗癌作用也可以在高耐药性肿瘤细胞<sup><a href=\"#quote_17\" class=\"kx_ref\">[17]</a></sup>和各种动物肿瘤模型中得到证实。<sup><a href=\"#quote_18\" class=\"kx_ref\">[18]</a></sup><sup><a href=\"#quote_19\" class=\"kx_ref\">[19]</a></sup> </p><p><h3>不利影响</h3></p><p>临床试验数据分析显示，与安慰剂相比，环氧合酶-2抑制剂导致的血管事件发生率显著增加；“血管事件”是指非致命性心肌梗塞（MI）或心脏病发作、非致命性中风以及由血管事件如心肌梗塞或中风导致的死亡。<sup><a href=\"#quote_20\" class=\"kx_ref\">[20]</a></sup><sup><a href=\"#quote_21\" class=\"kx_ref\">[21]</a></sup> 这些结果导致默克公司于2004年9月自愿从市场上召回(罗非昔布)，并向监管机构发出塞来昔布标签上的黑框警告。<sup><a href=\"#quote_20\" class=\"kx_ref\">[20]</a></sup>传统非甾体抗炎药也被发现有心血管风险，导致类似的黑框警告。<sup><a href=\"#quote_20\" class=\"kx_ref\">[20]</a></sup> </p><p>导致心血管问题的原因成为持续深入研究的课题。<sup><a href=\"#quote_22\" class=\"kx_ref\">[22]</a></sup>截至2012年，研究结果趋于一致，认为即造成心血管副作用最有可能原因是由于血管中环氧合酶-2的抑制，这导致血管中前列环素的产生减少。前列环素通常防止血小板聚集和血管收缩，因此其抑制作用会导致血栓形成和高血压。<sup><a href=\"#quote_22\" class=\"kx_ref\">[22]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"14996304723706382","title":"研究","versionId":"54263825834238218","lemmaId":11080,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":82859321,"name":"━╋独特","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1599639760,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p><h3>研究历史</h3></p><p>环氧合酶-2是由杨百翰大学研究员丹尼尔·西蒙斯（Daniel Simmons）于1988年发现。<sup><a href=\"#quote_23\" class=\"kx_ref\">[23]</a></sup> 1991年发表的一项发现是，加州大学洛杉矶分校科学家哈维·赫希曼博士克隆了小鼠环氧合酶-2基因。<sup><a href=\"#quote_24\" class=\"kx_ref\">[24]</a></sup> </p><p>导致环氧化酶-2抑制剂发现的基础研究已经至少涉及两起诉讼。杨百翰大学起诉辉瑞公司，指控其违反了西蒙斯博士在杨百翰大学工作时与该公司的关系。<sup><a href=\"#quote_25\" class=\"kx_ref\">[25]</a></sup><sup><a href=\"#quote_26\" class=\"kx_ref\">[26]</a></sup> 2012年4月达成和解，辉瑞同意支付4.5亿美元。<sup><a href=\"#quote_27\" class=\"kx_ref\">[27]</a></sup><sup><a href=\"#quote_28\" class=\"kx_ref\">[28]</a></sup> 另一项诉讼基于美国专利，罗切斯特大学拥有的美国专利号为6048850，<sup><a href=\"#quote_29\" class=\"kx_ref\">[29]</a></sup>该专利声称有一种通过选择性抑制环氧化酶-2来治疗疼痛而不引起胃肠不适的方法。当专利发布时，该大学起诉塞尔(后来的辉瑞公司)，案件名为罗切斯特大学诉塞尔公司，358 F.3d 916(联邦巡回法院，2004年)。法院在2004年作出了有利于塞尔的裁决，基本上认为该大学虽然声称有一种方法，要求能够抑制环氧化酶-2的化合物，但没有提供书面描述，因此该专利无效。<sup><a href=\"#quote_30\" class=\"kx_ref\">[30]</a></sup><sup><a href=\"#quote_31\" class=\"kx_ref\">[31]</a></sup> </p><p>在寻找前列腺素副作用的特定抑制剂而不产生积极效应的过程中，发现前列腺素确实可以分为两大类，根据参与其生物合成的特定酶环氧合酶的结构，这两大类可以粗略地被认为是“好的前列腺素”和“坏的前列腺素”。</p><p>合成涉及环氧酶-1或环氧合酶-1的前列腺素负责胃肠道的维持和保护，而合成涉及环氧酶-2或环氧合酶-2的前列腺素负责炎症和疼痛。</p><p>现有的非甾体抗炎药对环氧合酶-2和环氧合酶-1的相对特异性不同；虽然阿司匹林和布洛芬抑制环氧化酶-2和环氧化酶-1酶，但其他非甾体抗炎药似乎具有部分环氧化酶-2特异性，特别是美洛昔康（莫比可）。阿司匹林抑制环氧合酶-1的能力是环氧合酶-2的大约170倍。<sup><a href=\"#quote_32\" class=\"kx_ref\">[32]</a></sup>对美洛昔康进行每日7.5毫克为期23天的的研究发现，胃损伤水平与使用安慰剂相似，美洛昔康每日15毫克的损伤水平低于其他非甾体抗炎药；然而，在临床实践中，美洛昔康仍然会引起一些溃疡并发症。</p><p>伐地考昔和罗非考昔在抑制环氧化酶-2的效力上约为抑制环氧化酶-1的300倍，但对心脏毒性太大，表明有可能缓解疼痛和炎症，而不会刺激胃肠道，并有望对那些之前曾经历副作用或有可能导致此类并发症的共病患者有所裨益。塞来昔布抑制环氧化酶-2的效力大约是抑制环氧化酶-1的30倍，依托考昔的抑制环氧化酶-2效力是抑制环氧化酶-1的106倍。</p><p><h3>学术不端</h3></p><p>1996年至2009年间，麻醉师斯科特·鲁本(Scott Reuben)进行环氧化酶-2抑制剂临床应用研究，即环氧合酶-2抑制剂与加巴喷丁或普瑞巴林联合使用，用以预防和治疗术后疼痛，该研究在2009年被发现存在学术造假的问题。鲁本供认不讳，为此支付罚款，在监狱服刑六个月，同时医疗执照被撤销。<sup><a href=\"#quote_33\" class=\"kx_ref\">[33]</a></sup>2009年基于循证医学的荟萃分析文章的综述发现，尽管当鲁本研究被删除时，一些综述不再有效，但其中大多数的研究综述结论保持不变。<sup><a href=\"#quote_34\" class=\"kx_ref\">[34]</a></sup>该综述发现，鲁本研究中需要重新审查的是“脊柱手术后，环氧合酶抑制剂对骨愈合没有不利影响，预先服用环氧合酶抑制剂后有长期的有益结果，包括据称手术后慢性疼痛的发生率降低，以及酮咯酸或可乐定加入局部麻醉剂后用于静脉局部麻醉时的镇痛效果。”<sup><a href=\"#quote_34\" class=\"kx_ref\">[34]</a></sup> </p><p><h3><b>早期环氧合酶-2抑制药物</b></h3></p><p>塞来昔布(以及塞来昔布的其他品牌)于1999年推出，并迅速成为美国处方常用新药。到2000年10月，它在美国的年销售量超过1亿张处方，达到30亿美元，而且还在上升。仅西乐葆的销售额在2001年就达到了31亿美元。西班牙的一项研究发现，在2000年1月至2001年6月期间，7%的非甾体抗炎药处方和29%的非甾体抗炎药支出用于环氧合酶-2抑制剂。在研究期间，环氧合酶-2抑制剂从专科医生开出的总非甾体抗炎药的10.03%上升到29.79%，从初级保健医生开出的非甾体抗炎药的1.52%上升到10.78%(98.23%的非甾体抗炎药和94.61%的环氧合酶-2抑制剂由初级保健医生开出)。对于专科医师而言，罗非昔布和塞来昔布在最常用的非甾体抗炎药中分别位居第三和第五，但在成本上却分别位居第一和第二；对于初级保健医生来说，他们是第九和第十二位最常开的非甾体抗炎药，费用也是第一和第四位。</p><p>塞来昔布和万络迅速被医生广泛接受的原因两项大型试验的发表，即美国医学会杂志的塞来昔布长期应用于关节炎安全性研究<sup><a href=\"#quote_35\" class=\"kx_ref\">[35]</a></sup>和万络胃肠道预后研究(VIGOR)。<sup><a href=\"#quote_36\" class=\"kx_ref\">[36]</a></sup>该实验后来被证明是基于错误数据的研究，万络最终退出了市场。<sup><a href=\"#quote_37\" class=\"kx_ref\">[37]</a></sup> </p><p><strong><b>万络胃肠道预后研究与出版争议</b></strong></p><p>万络胃肠道预后结果研究（VIGOR）试验，“是默克公司罗非昔布的杰作”，<sup><a href=\"#quote_37\" class=\"kx_ref\">[37]</a></sup>它是医学期刊伦理争议的中心。万络胃肠道预后结果研究，是一项由 8000多名患者随机接受萘普生或罗非昔布(Vioxx)治疗的研究，其中一种环氧合酶-2抑制剂，默克希望它能减少胃肠道副作用。<sup><a href=\"#quote_37\" class=\"kx_ref\">[37]</a></sup>两份出版物都得出结论，环氧合酶-2特异性非甾体抗炎药与胃肠道副作用显著减少有关。在为期6个月的类试验中，比较西乐葆800毫克/天与布洛芬2400毫克/天和双氯芬酸150毫克/天治疗骨关节炎或类风湿性关节炎，西乐葆与明显较少的上消化道并发症相关(0.44%vs.1.27%，P=0.04)，未服用阿司匹林而进行心血管预防的患者心血管事件发生率无显著性差异。</p><p>万络胃肠道预后结果研究试验结果发表在2000年的《新英格兰医学杂志》上，<sup><a href=\"#quote_38\" class=\"kx_ref\">[38]</a></sup>庞巴迪和他的研究团队声称“服用罗非昔布的患者心肌梗死发生率(0.4%)高于服用萘普生的患者(0.1%)”，“服用萘普生的患者出现了121种副作用，而服用罗非昔布的患者出现了56种副作用”，这是“默克的惊人结果”，这“促成了罗非昔布的大量销售”<sup><a href=\"#quote_37\" class=\"kx_ref\">[37]</a></sup>。默克公司的科学家错误地将这一发现解释为萘普生的保护作用，告诉美国FDA心脏病发作的不同“主要是”由于“主要是由于”这种保护作用。<sup><a href=\"#quote_39\" class=\"kx_ref\">[39]</a></sup>[39]2001年9月，美国食品食品药品监督管理局(FDA)给默克公司首席执行官发了一封警告信，称“你们的促销活动歪曲了这样一个事实，即在万络胃肠道预后研究研究中，观察到服用万络的患者心肌梗塞(MIs)比服用对照非甾体抗炎药萘普生(NSAID)的患者增加了4到5倍。”<sup><a href=\"#quote_40\" class=\"kx_ref\">[40]</a></sup>这导致在2002年4月在万络标签上引入了关于心血管事件(心脏病发作和中风)风险增加的警告。到2005年，《新英格兰医学杂志》发表了一篇社论，指责庞巴迪等人故意隐瞒数据。<sup><a href=\"#quote_41\" class=\"kx_ref\">[41]</a></sup> </p><p>多伦多大学风湿病学家克莱尔·庞巴迪(Claire Bombardier)博士曾声称，VIGOR试验测试导致万络剂量为50毫克/天与萘普生治疗类风湿性关节炎相比，万络将症状性溃疡和临床上消化道事件(穿孔、阻塞和出血)的风险降低至54%，又从3%降至1.4%，将复杂上消化道事件(复杂穿孔、阻塞和上消化道出血)的风险降低至57%，从胃肠道任何部位出血的风险降至62%。这些出版物创造出了一个巨大的市场效应；根据国际监测系统健康中心的数据，万络是2000年广告宣传最多的处方药，西乐葆是第七名。</p><p><h3>神经母细胞瘤</h3></p><p>交感神经系统的小肿瘤(神经母细胞瘤)似乎有异常水平的环氧合酶-2表达。<sup><a href=\"#quote_42\" class=\"kx_ref\">[42]</a></sup>这些研究报告了环氧合酶-2的过度表达对肿瘤抑制因子p53有不利影响。p53是通常在细胞浆中发现的凋亡转录因子。当细胞的脱氧核糖核酸受损无法修复时，p53被转移到细胞核，在那里它促进p53介导的凋亡。<sup><a href=\"#quote_43\" class=\"kx_ref\">[43]</a></sup>环氧化酶-2的两种代谢物，前列腺素A2 (PGA2)和A1 (PGA1)，当它们大量存在时，与胞质溶胶中的p53结合并抑制其进入细胞核的能力。这基本上将p53隔离在细胞浆中并防止细胞凋亡。<sup><a href=\"#quote_43\" class=\"kx_ref\">[43]</a></sup>昔布类，如塞来昔布，通过选择性抑制过表达的环氧合酶-2，允许p53正常工作。功能性p53允许脱氧核糖核酸损伤的神经母细胞瘤细胞通过凋亡自杀，阻止肿瘤生长。</p><p>环氧合酶-2上调也与E3泛素连接酶HDM2的磷酸化和激活有关，HDM 2是一种通过泛素化介导p53连接和标记破坏的蛋白质。<sup><a href=\"#quote_43\" class=\"kx_ref\">[43]</a></sup>这种神经母细胞瘤HDM2过度活跃的机制尚不清楚。研究表明，环氧合酶-2抑制剂阻止HDM2的磷酸化，阻止其活化。在体外，环氧合酶-2抑制剂的使用降低了神经母细胞瘤细胞中活性HDM2的水平。环氧合酶-2抑制剂如何阻断HDM2磷酸化的确切过程尚不清楚，但这种介导的活性HDM2浓度水平的降低恢复了细胞p53水平。用环氧合酶-2抑制剂治疗后，恢复的p53功能允许受损伤的神经母细胞瘤细胞通过凋亡而自杀，从而减少肿瘤的生长。<sup><a href=\"#quote_43\" class=\"kx_ref\">[43]</a></sup> </p>","pics":null,"card":null,"references":[],"versionCount":0}],"references":[{"id":1,"type":"book","title":"Tirunagari SK, Derry S, Moore RA, McQuay HJ (2009). \"Single dose oral etodolac for acute postoperative pain in adults\". The Cochrane Database of Systematic Reviews (3): CD007357. doi:10.1002/14651858.CD007357.pub2. PMC 4164827. PMID 19588426.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":2,"type":"book","title":"Bulley S, Derry S, Moore RA, McQuay HJ (2009). \"Single dose oral rofecoxib for acute postoperative pain in adults\". The Cochrane Database of Systematic Reviews (4): CD004604. doi:10.1002/14651858.CD004604.pub3. PMC 4171390. PMID 19821329.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":3,"type":"book","title":"Clarke R, Derry S, Moore RA (May 8, 2014). \"Single dose oral etoricoxib for acute postoperative pain in adults\". The Cochrane Database of Systematic Reviews. 5 (5): CD004309. doi:10.1002/14651858.CD004309.pub4. PMID 24809657.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":4,"type":"book","title":"Derry S, Moore RA (Oct 22, 2013). \"Single dose oral celecoxib for acute postoperative pain in adults\". The Cochrane Database of Systematic Reviews. 10 (10): CD004233. doi:10.1002/14651858.CD004233.pub4. PMC 4161494. PMID 24150982.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":5,"type":"book","title":"van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landewé RB (16 September 2014). \"Non-steroidal anti-inflammatory drugs for acute gout\". The Cochrane Database of Systematic Reviews. 9 (9): CD010120. doi:10.1002/14651858.CD010120.pub2. PMID 25225849.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":6,"type":"book","title":"van Durme CM, Wechalekar MD, Landewé RB (Jun 2015). \"Nonsteroidal anti-inflammatory drugs for treatment of acute gout\". JAMA. 313 (22): 2276–7. doi:10.1001/jama.2015.1881. PMID 26057289.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":7,"type":"book","title":"\"COX-2 Inhibitors and Cancer\". Fact Sheet. United States National Cancer Institute. Archived from the original on May 9, 2008.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":8,"type":"book","title":"\"Archived copy\". Archived from the original on May 10, 2008. Retrieved May 8, 2008.CS1 maint: Archived copy as title (link)","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":9,"type":"book","title":"Chow LW, Loo WT, Toi M (Oct 2005). \"Current directions for COX-2 inhibition in breast cancer\". Biomedicine & Pharmacotherapy. 59 Suppl 2: S281–4. doi:10.1016/S0753-3322(05)80046-0. PMID 16507393.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":10,"type":"book","title":"Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, Gupta K (Dec 2007). \"COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia\". British Journal of Cancer. 97 (11): 1523–31. doi:10.1038/sj.bjc.6604057. PMC 2360252. PMID 17971769.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":11,"type":"book","title":"Müller N (Jan 2010). \"COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence\". Current Opinion in Investigational Drugs. 11 (1): 31–42. PMID 20047157.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":12,"type":"book","title":"Schönthal AH (Dec 2007). \"Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy\". British Journal of Cancer. 97 (11): 1465–8. doi:10.1038/sj.bjc.6604049. PMC 2360267. PMID 17955049.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":13,"type":"book","title":"Chuang HC, Kardosh A, Gaffney KJ, Petasis NA, Schönthal AH (2008). \"COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro\". Molecular Cancer. 7: 38. doi:10.1186/1476-4598-7-38. PMC 2396175. PMID 18485224.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":14,"type":"book","title":"Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS (Dec 2002). \"Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents\". Journal of the National Cancer Institute. 94 (23): 1745–57. doi:10.1093/jnci/94.23.1745. PMID 12464646.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":15,"type":"book","title":"Schönthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA (Feb 2008). \"Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs\". Expert Opinion on Investigational Drugs. 17 (2): 197–208. doi:10.1517/13543784.17.2.197. PMID 18230053.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":16,"type":"book","title":"Schönthal AH (2006). \"Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy\". Neurosurgical Focus. 20 (4): E21. doi:10.3171/foc.2006.20.4.14. PMID 16709027.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":17,"type":"book","title":"Kardosh A, Soriano N, Liu YT, Uddin J, Petasis NA, Hofman FM, Chen TC, Schönthal AH (Dec 2005). \"Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib\". Blood. 106 (13): 4330–8. doi:10.1182/blood-2005-07-2819. PMID 16123214.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":18,"type":"book","title":"Pyrko P, Kardosh A, Liu YT, Soriano N, Xiong W, Chow RH, Uddin J, Petasis NA, Mircheff AK, Farley RA, Louie SG, Chen TC, Schönthal AH (Apr 2007). \"Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib\". Molecular Cancer Therapeutics. 6 (4): 1262–75. doi:10.1158/1535-7163.MCT-06-0629. PMID 17431104.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":19,"type":"book","title":"Kardosh A, Wang W, Uddin J, Petasis NA, Hofman FM, Chen TC, Schönthal AH (May 2005). \"Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo\". Cancer Biology & Therapy. 4 (5): 571–82. doi:10.4161/cbt.4.5.1699. PMID 15846081.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":20,"type":"book","title":"Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA (Mar 2007). \"Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association\". Circulation. 115 (12): 1634–42. doi:10.1161/CIRCULATIONAHA.106.181424. PMID 17325246.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":21,"type":"book","title":"Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C (Jun 2006). \"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials\". BMJ. 332 (7553): 1302–8. doi:10.1136/bmj.332.7553.1302. PMC 1473048. PMID 16740558.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":22,"type":"book","title":"Cannon CP, Cannon PJ (Jun 2012). \"Physiology. COX-2 inhibitors and cardiovascular risk\". Science. 336 (6087): 1386–7. Bibcode:2012Sci...336.1386C. doi:10.1126/science.1224398. PMID 22700906.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":23,"type":"book","title":"Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (Apr 1991). \"Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing\". Proceedings of the National Academy of Sciences of the United States of America. 88 (7): 2692–6. Bibcode:1991PNAS...88.2692X. doi:10.1073/pnas.88.7.2692. PMC 51304. PMID 1849272.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":24,"type":"book","title":"Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (Jul 1991). \"TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue\". The Journal of Biological Chemistry. 266 (20): 12866–72. PMID 1712772.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":25,"type":"book","title":"Yajnik J (2006-10-27). \"University sues Pfizer over COX-2 research\". The Scientist. Retrieved 2010-11-11.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":26,"type":"book","title":"Tom Harvey (2010-09-21). \"BYU spices up Celebrex lawsuit against Pfizer\". The Salt Lake Tribune. Retrieved 2011-02-28.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":27,"type":"book","title":"Tom Harvey (May 1, 2012). \"Pfizer, BYU settle Celebrex lawsuit for $450M\". The Salt Lake Tribune.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":28,"type":"book","title":"Associated Press, May 1, 2012 Pfizer Settles B.Y.U. Lawsuit Over Development of Celebrex","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":29,"type":"book","title":"US Patent 6048850,","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":30,"type":"book","title":"\"Publications: Hodgson Russ LLP\". Hodgsonruss.com. Retrieved 2015-05-23.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":31,"type":"book","title":"Ranjana Kadle (2004) CAFC Court Decision Reach-Through Claims Declared Invalid Archived 2013-07-21 at the Wayback Machine","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":32,"type":"book","title":"Awtry EH, Loscalzo J (Mar 2000). \"Aspirin\". Circulation. 101 (10): 1206–18. doi:10.1161/01.cir.101.10.1206. PMID 10715270.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":33,"type":"book","title":"A Medical Madoff: Anesthesiologist Faked Data in 21 Studies, Scientific American, March 10, 2009","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":34,"type":"book","title":"Marret E, Elia N, Dahl JB, McQuay HJ, Møiniche S, Moore RA, Straube S, Tramèr MR (Dec 2009). \"Susceptibility to fraud in systematic reviews: lessons from the Reuben case\". Anesthesiology. 111 (6): 1279–89. doi:10.1097/ALN.0b013e3181c14c3d. PMID 19934873.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":35,"type":"book","title":"Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (Sep 2000). \"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study\". JAMA. 284 (10): 1247–55. doi:10.1001/jama.284.10.1247. PMID 10979111.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":36,"type":"book","title":"Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ (Nov 2000). \"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group\". The New England Journal of Medicine. 343 (21): 1520–8, 2 p following 1528. doi:10.1056/NEJM200011233432103. PMID 11087881.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":37,"type":"book","title":"Smith R (2006). \"Lapses at the new England journal of medicine\". Journal of the Royal Society of Medicine. 99 (8): 380–2. doi:10.1258/jrsm.99.8.380. PMC 1533509. PMID 16893926.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":38,"type":"book","title":"Bombardier C.; Laine L.; Reicin A. (2000). \"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis\". 343 (1520). New England Journal of Medicine.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":39,"type":"book","title":"\"NAME OF DRUG: Rofecoxib (MK-0966) : Memorandum\" (PDF). Fda.gov. Retrieved 4 January 2015.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":40,"type":"book","title":"\"Warning Letter\" (PDF). Fda.gov. Retrieved 4 January 2015.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":41,"type":"book","title":"Curfman GD, Morrissey S, Drazen JM (Dec 2005). \"Expression of concern: Bombardier et al., \"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,\" N Engl J Med 2000;343:1520-8\". The New England Journal of Medicine. 353 (26): 2813–4. doi:10.1056/NEJMe058314. PMID 16339408.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":42,"type":"book","title":"Johnsen JI, Lindskog M, Ponthan F, Pettersen I, Elfman L, Orrego A, Sveinbjörnsson B, Kogner P (Oct 2004). \"Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo\". Cancer Research. 64 (20): 7210–5. doi:10.1158/0008-5472.CAN-04-1795. PMID 15492235.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":43,"type":"book","title":"Lau L, Hansford LM, Cheng LS, Hang M, Baruchel S, Kaplan DR, Irwin MS (Mar 2007). \"Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma\". Oncogene. 26 (13): 1920–31. doi:10.1038/sj.onc.1209981. PMID 16983334.","site":"","url":"","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false}],"recommendReferences":null,"auditState":2,"lemmaLevel":1,"origin":0,"originEnTitle":null,"originZhTitle":null,"pv":10839,"auditType":0,"synonyms":null,"showEditTime":"2019.12.13 18:54","auditors":[{"uid":0,"name":"Ki.κe","pic":"https://web.archive.org/web/20221025090628/https://wx.qlogo.cn/mmopen/vi_32/y67kfr32Doib4wg71Jiau7jVWvharic3nRKgdRRQSl6koeQJCo0GQs2Krw0vwdFRsOWnHIQOwAZsSg5lIkIrFCOcQ/132","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false}],"hasZhishiNav":false,"auditInfos":{},"isHistory":false};</script><script crossorigin="anonymous" src="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/aegis.min.js.download"></script><script crossorigin="anonymous" src="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/main_2020092401.js.download"></script><script crossorigin="anonymous" src="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/jquery-1.11.1.min.js.download"></script><script crossorigin="anonymous" src="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/main_2022062701.js.download"></script><script crossorigin="anonymous" src="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/main_66bbe21.js.download"></script><script crossorigin="anonymous" src="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./1080.选择性COX2抑制剂 - 搜狗科学百科_files/main_edf0f08.js.download"></script><div id="popControl"><div class="pop-control-mask" style="display: none;"><div class="pop-container"><i class="close-icon"></i><div class="stop-title">搜狗科学百科停止服务运营公告</div><div class="stop-user">亲爱的用户：</div><div class="stop-content">因业务方向调整，搜狗科学百科将于2022年11月11日正式停止服务与运营。届时产品内所有数据将依据相关法律进行删除并关闭服务器，您将无法登录及使用搜狗科学百科，相关内容在平台下线后将无法找回。</div><div class="stop-content">搜狗科学百科是由搜狗推出的科学领域专业百科产品，与搜狗百科为两个独立产品，本次停止服务与运营仅对搜狗科学百科，并不影响搜狗百科产品正常使用，敬请知悉。</div><div class="stop-content">由此给您带来的不便我们深表歉意，敬请谅解。再次感谢您一直以来的陪伴与支持！</div><div class="stop-team">搜狗科学百科产品&amp;运营团队</div><div class="stop-time">2022年10月11日</div></div></div></div>
</body></html>